-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 3-5% of breast cancer patients have BRCA1 or BRCA2 gene mutations, which is the cause of about 28% of high-risk hereditary breast cancers
.
Previous studies have shown that BRCA1/2 mutation carriers have an increased risk of developing contralateral breast cancer, the risk of BRCA1 mutations is the highest, and the patientsare younger when they arefirst diagnosed with breast cancer
About 3-5% of breast cancer patients have BRCA1 or BRCA2 gene mutations, which is the cause of about 28% of high-risk hereditary breast cancers
The two breast cancer susceptibility genes BRCA1 and BRCA2 are located on chromosomes 17 and 13, respectively.
Mutations in the BRCA gene can lead to DNA repair defects and an increased risk of early-onset breast cancer
.
The prognostic value of tumor infiltrating lymphocytes (TIL) in breast cancer has been recognized
.
However, there are still few studies on specific T cell subsets of BRCA-related breast cancer
Distribution of immune marker expression
Immunological marker expression profile of immuneIn this study, the researchers analyzed tumor tissues from 414 breast cancer patients with BRCA mutations, and detected the expression levels of CD4, CD8, and FOXP3 immune markers through immunohistochemistry and digital image analysis
.
According to the analysis of low expression group or high expression group, the distribution and clinicopathological characteristics of CD4, CD8 and FOXP3 positive cells were evaluated
The researchers analyzed tumor tissues from 414 breast cancer patients with BRCA mutations, and used immunohistochemistry and digital image analysis to detect the expression levels of CD4, CD8 and FOXP3 immune markers
Analysis of patient survival rate
Analysis of patient survival rateThe results showed that the expression levels of CD4 and CD8 were related to the histological diagnosis of the disease, tumor grade, and the expression status of estrogen and progesterone receptors
.
The expression level of CD4 is correlated with BRCA gene status
All in all, the results of this study support the prognostic role of specific T cell subsets in BRCA-associated breast cancer and the potential of targeting the immune system to treat the disease
.
The results of this study support the prognostic role of specific T cell subsets in BRCA-related breast cancer and the potential of targeting the immune system to treat the disease
.
The results of this study support the prognostic role of specific T cell subsets in BRCA-related breast cancer and the potential of targeting the immune system to treat the disease
Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
Leave a message here